



**LUMOS**  
DIAGNOSTICS

## ASX ANNOUNCEMENT

### **Lumos Secures Additional U.S. Medicare Reimbursement Coverage for FebriDx® with a Further Two MACs**

#### **Key Highlights**


- Lumos has secured reimbursement coverage for FebriDx® from two additional Medicare Administration Contractors (MACs) at US\$41.38 per test, retroactive from 1 April 2025.
- US reimbursement coverage now achieved with four of seven MACs, representing over 55% of US Medicare payment coverage.
- Momentum continues with negotiations in process with the remaining three MACs.
- Medicare adoption generally serves as a precedent for reimbursement decisions by private insurance payors.

**MELBOURNE, Australia (23 April 2025)** – Lumos Diagnostics (ASX: LDX), (“Lumos” or the “Company”) a leader in rapid, point-of-care diagnostic technologies, is pleased to announce that it has received confirmation of Medicare reimbursement coverage from two additional Medicare Administrative Contractors (MACs), First Coast Service Options (FCSO) and Noridian Healthcare Solutions (Noridian). FebriDx will be included in the Medicare Fee Schedule of FCSO and Noridian, retroactive from 1 April 2025.

FCSO is responsible for managing Medicare payments in the state of Florida, while Noridian provides coverage across a wide geographic region that includes California, Nevada, Oregon, Washington, Idaho, Montana, Utah, Arizona, Wyoming, North Dakota, South Dakota, Alaska and Hawaii.

With the inclusion of these two MACs, to the previously announced coverage from Novitas and Palmetto (ASX: 17 April 2025), Lumos now has Medicare reimbursement from four of the seven MACs, representing over 55% of the total US Medicare payment coverage. This continued momentum in the Company’s commercialisation efforts significantly expands Lumos’ access to the Medicare patient population.

Map of U.S. MAC Jurisdictions



Achieving reimbursement coverage is a critical validation milestone on the pathway to meaningful adoption of FebriDx in the U.S. Over time, commercialisation success will be driven by demonstrating three essential outcomes:

1. **Clear clinical benefit** – evidence that the test improves patient care;
2. **Impact on the clinical care pathway** – showing that the test makes the diagnostic and treatment process more efficient or effective; and
3. **Favourable economics** – proving that the test is financially beneficial for the healthcare system.

Commenting on the announcement, Doug Ward, Managing Director of Lumos Diagnostics said: *“Securing additional Medicare coverage from FCSO and Noridian for FebriDx reinforces our commitment to developing a point-of-care diagnostic solution that not only benefits patients, but also integrates seamlessly into care pathways and delivers value to the broader health system.”*

*“Lumos remains committed to securing adoption from the remaining three MACs and pursuing reimbursement coverage from private payors, with the goal of achieving nationwide access for patients and supporting broad clinical adoption of FebriDx.”*

-Ends-

***This announcement has been approved by the Lumos Disclosure Committee.***

## About Lumos Diagnostics

Lumos Diagnostics specializes in rapid and complete point-of-care diagnostic test technology to help healthcare professionals more accurately diagnose and manage medical conditions. Lumos offers customized assay development and manufacturing services for point-of-care tests and proprietary digital reader platforms. Lumos also directly develops, manufactures, and commercializes novel Lumos-branded point-of-care tests that target infectious and inflammatory diseases.

For more information visit [lumosdiagnostics.com](http://lumosdiagnostics.com).

## Forward-Looking Statements

*This announcement contains forward-looking statements, including references to forecasts. Forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties, assumptions, and other important factors, many of which are beyond Lumos' control and speak only as of the date of this announcement. Readers are cautioned not to place undue reliance on forward-looking statements.*

### Media Contact:

Haley Chartres – Australia  
HACK Director  
[haley@hck.digital](mailto:haley@hck.digital)  
+61 (0) 423 139 163

### Investor Contact:

George Kopsiaftis  
IR Department  
[ir@lumosdiagnostics.com](mailto:ir@lumosdiagnostics.com)  
+61 409 392 687

### Company Registered Office:

Lumos Diagnostics Holdings Ltd  
Level 4, 100 Albert Rd  
South Melbourne, VIC 3205, Australia  
+61 3 9087 1598